Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Celgene Corp (NASDAQ:CELG)

112.19
Delayed Data
As of Jul 29
 +0.93 / +0.84%
Today’s Change
92.98
Today|||52-Week Range
136.40
-6.32%
Year-to-Date
3 Biotech Stocks to Buy on Sale
9:07am / MotleyFool.com - Paid Partner Content
Beware of False Profits
Jul 26 / TheStreet.com - Paid Partner Content
Company News for July 29, 2016
Jul 29 / Zacks.com - Paid Partner Content
An Investing Overview of the Multiple Sclerosis Market
Jul 26 / MotleyFool.com - Paid Partner Content
Celgene Corporation Nails the Second Quarter
Jul 29 / MotleyFool.com - Paid Partner Content
Celgene Can't Expand Revlimid Approval into Non-Hodgkin Lymphoma Just Yet
Jul 25 / TheStreet.com - Paid Partner Content
Celgene's Otezla Is A Big Hit
Jul 28 / MotleyFool.com - Paid Partner Content
3 Top Biotech Stocks to Buy Now
Jul 25 / MotleyFool.com - Paid Partner Content
This Small Gain Is a Big Win for Celgene Corporation
Jul 28 / MotleyFool.com - Paid Partner Content
Celgene (CELG) Q2 Earnings: Can the Stock Pull a Surprise?
Jul 25 / Zacks.com - Paid Partner Content
Hep C Business Slow-Down Could Hamper Bristol-Myers' Future
Jul 28 / TheStreet.com - Paid Partner Content
I'm Bullish on Biotechs
Jul 25 / TheStreet.com - Paid Partner Content
Celgene (CELG) Tops Q2 Earnings & Revenues, Lifts View
Jul 28 / Zacks.com - Paid Partner Content
I Just Bought These 4 Fast-Growing Biotech Stocks
Jul 23 / MotleyFool.com - Paid Partner Content
3 Stocks That Could Double Your Money
Jul 28 / MotleyFool.com - Paid Partner Content
Stock Market News for July 21, 2016
Jul 21 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Jul 28 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Zafgen, Celgene, Amgen, AbbVie and Biogen
Jul 21 / Zacks.com - Paid Partner Content
Pre-Market Activity Shows Gains For Celgene (CELG)
Jul 28 / TheStreet.com - Paid Partner Content
Biotech Stock Roundup: Celgene in Immuno-Oncology Deal, Zafgen Drops Lead Drug
Jul 20 / Zacks.com - Paid Partner Content
Celgene (CELG) Beats on Q2 Earnings and Revenues
Jul 28 / Zacks.com - Paid Partner Content
Celgene (CELG), Jounce Strike Immunotherapy Collaboration
Jul 20 / Zacks.com - Paid Partner Content
Celgene 2Q Earnings Yield No Surprises, Small Guidance Bump
Jul 28 / TheStreet.com - Paid Partner Content
3 Perfect Stocks for People in Their 40s to Consider Buying
Jul 20 / MotleyFool.com - Paid Partner Content
Celgene (CELG) Stock Climbs on Q2 Earnings, Revenue Beat
Jul 28 / TheStreet.com - Paid Partner Content
3 Biotech Stocks to Buy and Hold
Jul 19 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Jul 27 / Zacks.com - Paid Partner Content
Celgene to partner Jounce in battle against cancerous cells
Jul 19 / FT.com - Paid Partner Content
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Jul 27 / Zacks.com - Paid Partner Content
Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Jul 18 / Zacks.com - Paid Partner Content
3 Things to Watch as Celgene Corporation Reports Earnings
Jul 26 / MotleyFool.com - Paid Partner Content
Cancer drug trial deaths hit biotech industry
Jul 08 / FT.com - Paid Partner Content
3 Stocks Dragging The Health Care Sector Downward
Jul 26 / TheStreet.com - Paid Partner Content
Medivation: scarcity value
Jul 06 / FT.com - Paid Partner Content
Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook
Jul 26 / TheStreet.com - Paid Partner Content
Medivation confident drugs pipeline will win over suitors
Jul 06 / FT.com - Paid Partner Content
Trade of the Week: Long SPY Puts
Jul 26 / TheStreet.com - Paid Partner Content
Wall Street set for best week since late 2014 as stocks rebound
Jul 01 / FT.com - Paid Partner Content
Morning Movers: BUD, VZ, CELG, GS
Jul 26 / TheStreet.com - Paid Partner Content